Delhi High Court seeks Centre’s reply on Remdesivir
[ad_1]
The Delhi High Court on Monday requested the Centre and a number of other pharmaceutical firms to reply to a petition looking for that every one producers of Remdesivir, utilized in COVID-19 remedy, be allowed to promote it within the home market.
A Bench of Chief Justice D.N. Patel and Justice Jasmeet Singh issued discover to the Health Ministry, Central Drugs Standard Control Organisation, Director General of Foreign Trade and varied corporations reminiscent of Cipla, Zydus and Cadila.
The plea claimed that solely a handful of pharma firms are allowed to promote the drugs within the home market.
It claimed that there are greater than 25 firms which manufacture the drugs, however solely six to eight of them are permitted to promote it within the home market and the remainder had been producing it for exports alone.
It requested for route to the remaining firms concerned in manufacturing the drug for export to promote it within the home market.
“It is pertinent to mention that the scarcity of Remdesivir is causing its extensive black marketing and the black marketers are charging prices up to ₹1,00,000 per vial, due to its non-availability.”
[ad_2]
